The company develops a multimodal approach that employs a combination of engineered viruses and small molecules to modulate the STING pathway to treat cancer and infectious diseases, allowing patients to harness their immune systems. They are also developing non-nucleotidic small molecule inhibitors for the treatment of cancer and infectious diseases.